X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (26) 26
humans (24) 24
female (19) 19
lung cancer (16) 16
oncology (15) 15
aged (14) 14
male (14) 14
middle aged (13) 13
chemotherapy (11) 11
lung neoplasms - drug therapy (11) 11
adult (10) 10
air-conditioning, air-humidification, ventilation, use of aircurrents for screening (9) 9
blasting (9) 9
cancer (9) 9
carcinoma, non-small-cell lung - drug therapy (9) 9
epidermal growth factor (9) 9
heating (9) 9
lighting (9) 9
mechanical engineering (9) 9
ranges (9) 9
ventilating (9) 9
weapons (9) 9
aged, 80 and over (8) 8
mutation (8) 8
gefitinib (7) 7
medicine & public health (7) 7
open-label (7) 7
prospective studies (7) 7
tyrosine (7) 7
cancer research (6) 6
carboplatin (6) 6
cisplatin (6) 6
non-small cell lung cancer (6) 6
osimertinib (6) 6
analysis (5) 5
antineoplastic agents - therapeutic use (5) 5
electricity (5) 5
epidermal growth factor receptors (5) 5
lung cancer, non-small cell (5) 5
non-small cell lung carcinoma (5) 5
prognosis (5) 5
prospective feasibility (5) 5
research (5) 5
t790m (5) 5
tumors (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
calculating (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
cisplatin-based chemotherapy (4) 4
computing (4) 4
counting (4) 4
erlotinib (4) 4
follow-up studies (4) 4
hematology, oncology and palliative medicine (4) 4
low-volume hydration (4) 4
lung neoplasms - genetics (4) 4
lung neoplasms - pathology (4) 4
mutations (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
physics (4) 4
pulmonary/respiratory (4) 4
risk factors (4) 4
survival (4) 4
young adult (4) 4
1st-line treatment (3) 3
antineoplastic agents - adverse effects (3) 3
carcinoma, non-small-cell lung - pathology (3) 3
care and treatment (3) 3
circuit arrangements or systems for supplying or distributingelectric power (3) 3
cisplatin - administration & dosage (3) 3
clinical trials (3) 3
conversion or distribution of electric power (3) 3
drug resistance, neoplasm - drug effects (3) 3
gene-mutations (3) 3
generation (3) 3
genetic aspects (3) 3
japan (3) 3
lung cancer, small cell (3) 3
mutation - genetics (3) 3
non-small-cell lung cancer (3) 3
pharmacology & pharmacy (3) 3
pharmacology/toxicology (3) 3
phase-iii (3) 3
protein kinase inhibitors - therapeutic use (3) 3
protein-tyrosine kinase (3) 3
quinazolines - therapeutic use (3) 3
receptor, epidermal growth factor - genetics (3) 3
respiratory system (3) 3
ribonucleic acid--rna (3) 3
surgical oncology (3) 3
systems for storing electric energy (3) 3
trastuzumab emtansine (3) 3
urology & nephrology (3) 3
1st-line (2) 2
acquired-resistance (2) 2
adenocarcinoma (2) 2
afatinib (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 1955 - 11
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 10/2018, Volume 18, Issue 10, pp. 1015 - 1021
Introduction: Platinum-based chemotherapy had long played a role as standard therapy for the first-line treatment of advanced or recurrent non-small cell lung... 
non-small cell lung cancer | PD-L1 | Pembrolizumab | checkpoint inhibitors | first-line | MEDICINE, RESEARCH & EXPERIMENTAL | CARBOPLATIN | PD-1 BLOCKADE | INDOLEAMINE 2,3-DIOXYGENASE | OPEN-LABEL | REGULATORY T | PROSPECTIVE FEASIBILITY | CISPLATIN-BASED CHEMOTHERAPY | LOW-VOLUME HYDRATION | MELANOMA | IMMUNOTHERAPY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 5/2019, Volume 24, Issue 5, pp. 461 - 467
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 01/2019, Volume 24, Issue 1, pp. 41 - 45
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances... 
Re-biopsy | Lung cancer | Treatment | SPATIOTEMPORAL T790M HETEROGENEITY | OPEN-LABEL | PROSPECTIVE FEASIBILITY | CISPLATIN-BASED CHEMOTHERAPY | LOW-VOLUME HYDRATION | EGFR-MUTANT | ONCOLOGY | ALECTINIB | MUTATIONS | 1ST-LINE | EXPRESSION
Journal Article
Internal Medicine, ISSN 0918-2918, 2017, Volume 56, Issue 5, pp. 551 - 555
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 12/2018, Volume 82, Issue 6, pp. 1031 - 1038
The aim of this study was to evaluate the efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) readministration using afatinib... 
EGFR mutation | Readministration | Medicine & Public Health | Afatinib | Non-small-cell lung cancer | Oncology | Cancer Research | T790M | EGFR-TKI | Pharmacology/Toxicology | 1ST-LINE TREATMENT | GEFITINIB | METAANALYSIS | ADENOCARCINOMA | OPEN-LABEL | PROSPECTIVE FEASIBILITY | CISPLATIN-BASED CHEMOTHERAPY | LOW-VOLUME HYDRATION | ONCOLOGY | PHARMACOLOGY & PHARMACY | JAPANESE PATIENTS | ERLOTINIB | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Afatinib - administration & dosage | ErbB Receptors - antagonists & inhibitors | Lung Neoplasms - enzymology | Drug Administration Schedule | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Male | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Genes, erbB-1 | Antineoplastic Agents - adverse effects | Survival Analysis | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Afatinib - adverse effects | Afatinib - therapeutic use | Tyrosine | Chemotherapy | Epidermal growth factor | Oncology, Experimental | Clinical trials | Genetic aspects | Product development | Research | Lung cancer, Non-small cell | Cancer | Creatinine | Epidermal growth factor receptors | Toxicity | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Cytotoxicity | Disease control | Survival | Patients | c-Met protein | Confidence intervals | Lungs | Hypokalemia | Growth factors | Cytotoxic agents | Protein-tyrosine kinase | Tumors | Index Medicus
Journal Article
Clinical and Experimental Nephrology, ISSN 1342-1751, 06/2017, Volume 21, Issue 3, pp. 465 - 473
Journal Article
Lung Cancer, ISSN 0169-5002, 06/2019, Volume 132, pp. 54 - 58
Osimertinib is a tyrosine kinase inhibitor (TKI) that is an essential agent for the treatment of ( )-mutant non-small-cell lung cancer (NSCLC). However, there... 
EGFR mutation | Non-small-cell lung cancer | Osimertinib | EGFR TKI | T790M | Re-administration | Tyrosine | Epidermal growth factor
Journal Article
Lung Cancer, ISSN 0169-5002, 10/2019, Volume 136, pp. 86 - 93
Lung cancers harboring ( ) mutations inevitably develop resistance to EGFR tyrosine-kinase inhibitors (EGFR-TKIs). Therefore, we sought to establish clinically... 
Osimertinib | EGFR mutations | Acquired resistance | NSCLC | Transgenic mice | Tyrosine | Genetic aspects | Epidermal growth factor | Analysis
Journal Article
Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 50, pp. 29525 - 29531
Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy... 
Osimertinib | T790M | Rebiopsy | Lung cancer | EGFR
Journal Article
Japanese Journal of Lung Cancer, ISSN 0386-9628, 2018, Volume 58, Issue 5, pp. 325 - 330
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2016, Volume 78, Issue 5, pp. 941 - 947
Being overweight has been reported to induce hepatic dysfunction during cytotoxic chemotherapy. Severe hepatic dysfunction can also be observed during... 
Medicine & Public Health | EGFR-tyrosine kinase inhibitor | Lung cancer | Oncology | Cancer Research | Hepatic dysfunction | Pharmacology/Toxicology | Gefitinib | Overweight | 1ST-LINE TREATMENT | MULTICENTER | OPEN-LABEL | CHEMOTHERAPY | POLYMORPHISMS | PHARMACOKINETICS | ONCOLOGY | PHARMACOLOGY & PHARMACY | AFATINIB | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Overweight - complications | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Retrospective Studies | Chemical and Drug Induced Liver Injury - etiology | Body Mass Index | Liver Function Tests | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Risk Factors | Chemical and Drug Induced Liver Injury - epidemiology | Mutation - genetics | Lung Neoplasms - complications | Carcinoma, Non-Small-Cell Lung - complications | Asian Continental Ancestry Group | Quinazolines - therapeutic use | Quinazolines - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Obesity | Oncology, Experimental | Lung cancer, Small cell | Respiratory agents | Disease susceptibility | Research | Lung cancer, Non-small cell | Risk factors | Chemotherapy | Epidermal growth factor | Analysis | Cancer
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.